UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 1, 2021

Registrant’s telephone number, including area code: (212) 949-4319

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

The information disclosed under Item 5.07 is incorporated herein by reference.

On March 4, 2021, PAVmed Inc. (the “Company”) held a special meeting of stockholders (the “2021 Special Meeting”). Stockholders representing a majority of the shares outstanding and entitled to vote were present in person or by proxy. The stockholders approved all the matters considered at the 2021 Special Meeting, each of which is set forth below along with a tally of the votes on such matter.

As described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on January 27, 2021 (the “Definitive Proxy Statement”), certain of the proposals were previously submitted for consideration by the Company’s stockholders at the Company’s annual meeting of stockholders held on July 24, 2020. Because there may have been uncertainty regarding the validity or effectiveness of the approval of these proposals at the annual meeting due to the treatment of broker non-votes, the Company resubmitted these proposals for ratification and/or approval at the 2021 Special Meeting.

1. (a) A proposal to approve the issuance of shares of the Company’s common stock to Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (“Alto B”) under the Senior Convertible Note issued by the Company in April 2020, for purposes of Nasdaq Listing Rule 5635.

The issuance was approved, as follows:

(b) A proposal to approve the issuance of shares of the Company’s common stock to Alto B under the Senior Secured Convertible Note issued by the Company in August 2020, for purposes of Nasdaq Listing Rule 5635.

The issuance was approved, as follows:

A fuller description of the transactions with Alto B is set forth on pages 7 to 16 of the Definitive Proxy Statement, which description is incorporated herein by reference.

Notwithstanding the approval, no shares will be issued under the convertible notes, as the Company repaid the convertible notes in full on March 2, 2021, as previously disclosed.

2. A proposal to ratify and approve an amendment to the Company’s 2014 Long-Term Incentive Equity Plan, as amended (the “2014 Plan”), to increase total number of shares of the Company’s common stock available under the 2014 Plan by an additional 2,000,000 shares, from 7,951,081 shares to 9,951,081 shares.

The amendment to the 2014 Plan was ratified and approved, as follows:

A fuller description of the 2014 Plan, as amended, is set forth on pages 17 to 24 of the Definitive Proxy Statement, which description is incorporated herein by reference. The description of the 2014 Plan from the Definitive Proxy Statement does not purport to be complete and is qualified in its entirety by reference to the full text of the 2014 Plan, which is included as Exhibit 10.1 to this current report on Form 8-K and is incorporated herein by reference.

3. A proposal to ratify and approve an amendment to the Company’s Employee Stock Purchase Plan (the “ESPP”) to increase the total number of shares authorized for employee purchase by 500,000 shares, from 250,000 shares to 750,000 shares.

The amendment to the ESPP was ratified and approved, as follows:

A fuller description of the ESPP, as amended, is set forth on pages 25 to 30 of the Definitive Proxy Statement, which description is incorporated herein by reference. The description of the ESPP from the Definitive Proxy Statement does not purport to be complete and is qualified in its entirety by reference to the full text of the ESPP, which is included as Exhibit 10.2 to this current report on Form 8-K and is incorporated herein by reference.

Because each of the foregoing proposals were approved, the proposal to approve the adjournment of the 2021 Special Meeting, if necessary, to solicit additional proxies, was not presented.

In addition, effective as of March 1, 2021, the base salaries of Lishan Aklog, M.D., the Chairman and Chief Executive Officer of the Company, and Dennis M. McGrath, the President and Chief Financial Officer of the Company, were increased to rates of $613,000 per year and $438,000 per year, respectively. In addition, effective as of such date, the board of directors of Lucid Diagnostics, Inc. (“Lucid”), a subsidiary of the Company, granted restricted stock awards to each of Dr. Aklog and Mr. McGrath. Dr. Aklog was granted 400,000 shares of restricted stock of Lucid and Mr. McGrath was granted 400,000 shares of restricted stock of Lucid. Each award vests on the second anniversary of the grant.

(d) Exhibits:

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.